AbbVie in talks to sell $5B women's drugs portfolio

March 20, 2021

AbbVie (NYSE:ABBV) is in discussions to sell a ~$5B portfolio of women's drugs it acquired last year through its purchase of Allergan , Reuters reports.

AbbVie is working with Morgan Stanley on an auction process that has attracted interest from private equity firms including CVC Capital Partners, according to the report.

The portfolio reportedly generates 12-month EBITDA of ~$500M and could be valued at ~10x its EBITDA.

AbbVie has been relying on its blockbuster Humira to drive up sales and beat forecasts, but with the drug's U.S. patent protection expiring in 2023, AbbVie needs to pay down a large debt amassed through the Allergan purchase in order to focus on new investments.

Over the current book year the total revenue from the company in North Chicago will be 55.31 billion USD (consensus estimates). This is quite more than 2020's revenue of 45.8 billion USD.

Historical revenues and results Abbvie plus estimates 2020

The analysts expect for 2021 a net profit of 22.14 billion USD. The majority of the analysts expects for this year a profit per share of 12.45 USD. The price/earnings-ratio is then 8.31.

Huge dividend Abbvie

For this year most of the analysts expect a dividend of 5.14 USD per share. Thus the dividend yield equals 4.97 percent. The average dividend yield of the biotech companies is a limited 0.37 percent.

Abbvie 's market capitalization is around 152.95 billion USD. The Abbvie stock was the past 12 months quite unstable. Since last March the stock is even 54 percent higher. This year the stock price moved between 63 and 113 dollar.

Historical stock prices Abbvie

Click here for dividend Abbvie. On Friday, the stock closed at 103.42 USD.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

Other stock news

Currently quite high dividend Abbvie

Analysts expect over 2021 rising revenue Abbvie, relatively high dividend

Analysts expect over 2021 rising revenue Abbvie, quite high dividend

Analysts: more sales Abbvie, huge dividend

AbbVie to sell Allergan Biologics to Pharmaron for $119 million

Analysts expect over 2020 rising revenue Abbvie, relatively high dividend

Analysts foresee more revenue Abbvie, huge dividend

Sector news

Analysts expect sales decline Biogen

Currently quite high dividend BB Biotech

Analysts: more sales Pharming

Analysts count on revenue increase Pharming

Gilead Sciences in top American dividend stocks

Analysts estimate for 2023 rising sales Sartorius

Currently quite high dividend Abbvie

National news

NXP reaps benefits from FRAMOS collaboration

Tesla net onder de 500.000 cars per year

Analysts expect over 2024 revenue decrease Caterpillar

Analysts expect sales decline Biogen

Analysts anticipate for 2024 on revenue increase Cognizant

Analysts expect over 2024 growing sales Colgate-Palmolive

Analysts expect over 2024 revenue expansion Patterson-UTI Energy, relatively high dividend

Press news

Test News

Aquis Stock Exchange: withdrawal from trading

LHV Bank initiated coverage of Eleving Group

District Metals Corp.: District Comments on Uranium Mining Announcement from the Swedish Government

Andreas Wyss is running for election to the Board of Directors of the mobilezone Group

Siegfried once again confirmed in the Dow Jones Sustainability Index Europe

The notes redeemed by Municipality Finance have been removed from trading at Nasdaq Helsinki

About us	Network	Partners
Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos	Analist.nlLinksISIN Glossary	MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x